Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
BioNTech, Genentech cancel ph. 2 test of personalized cancer vax
An independent safety board recommended the trial be terminated early after more deaths were observed in patients given the customized mRNA vaccine.
Darren Incorvaia
Aug 28, 2026 1:50pm
Regeneron ends eye disease trial following safety review
Aug 17, 2026 2:30pm
AstraZeneca ends phase 3 cancer trial as bispecific underwhelms
Aug 17, 2026 4:45am
Sionna’s cystic fibrosis flop a ‘significant’ boost for Vertex
Aug 10, 2026 9:38am
BioMarin axes $270M asset after missing phase 3 endpoint
Aug 7, 2026 9:10am
Double shot of Vistagen’s anxiety nasal spray misses in ph. 2
Aug 6, 2026 10:32am
